Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease, caused by dysregulation of the alternative complement pathway, characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal insufficiency, in the absence of positive Shiga toxin or ADAMTS13 deficiency. First line treatment is eculizumab, that allows for, in most of cases, a complete remission within six months. We present the case of an atypical late renal response to eculizumab administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
